leadf
logo-loader
viewBioasis Technologies Inc.

Bioasis Technologies forms 'exciting' licensing agreement with Chiesi Global Rare Diseases

Bioasis Technologies Inc (CVE:BTI) (OTCQB:BIOAF) CEO Deborah Rathjen tells Proactive the Canada-based firm and Italy-based Chiesi Global Rare Diseases have entered into a licensing agreement for Bioasis’ xB3 BBB platform technology to treat rare diseases with a focus on four undisclosed lysosomal storage disorders (LSDs).

Rathjen says under the terms of the agreement, international research-focused healthcare firm Chiesi Group, the parent of Chiesi Global Rare Diseases, will pay Bioasis an upfront payment of US$3 million.

Quick facts: Bioasis Technologies Inc.

Price: 0.235 USD

OTCQB:BIOAF
Market: OTCQB
Market Cap: $15.95 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Bioasis Technologies Inc. named herein, including the promotion by the Company of Bioasis Technologies Inc. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Bioasis Technologies says revenue potential for brain metastasis of breast...

Bioasis Technologies Inc. (OTCQB:BIOAF)(TSX.V:BTI) CEO Deborah Rathjen sat down with Proactive’s Christine Corrado at BIO CEO & Investor Conference in New York. Rathjen explains how the revenue potential for brain metastasis of breast cancer is $404M. Bioasis has developed its proprietary...

on 11/2/20

2 min read